Chengdu Easton Biopharmaceuticals Co., Ltd.
SHH: 688513.SS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mingxu Yuan
- Employees
- 1,400
- Headquarters
- Chengdu, China
- IPO year
- 2020
- Market cap
- CN¥11.1B
- Website
- https://www.eastonpharma.cn
Loading 688513…
Loading profile data…Frequently asked questions about 688513
What does Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) do?
Chengdu Easton Biopharmaceuticals Co., Ltd. engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms in anesthetic/analgesics, cardiovascular, oncology, pediatrics, and other therapeutic fields. It also offers active pharmaceutical ingredients in oncology, car...
Where does 688513.SS trade?
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) trades on the Shanghai Stock Exchange.
What sector is 688513.SS in?
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Chengdu Easton Biopharmaceuticals Co., Ltd.?
Mingxu Yuan is the chief executive officer of Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS).
Where is Chengdu Easton Biopharmaceuticals Co., Ltd. headquartered?
Chengdu Easton Biopharmaceuticals Co., Ltd. is headquartered in China.
Does 688513.SS pay a dividend?
Yes — Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) paid a trailing twelve-month dividend of CNY 0.43 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 688513.SS go public?
Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS) completed its initial public offering in 2020.